GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2007

Agilent Takes Over Stratagene

  • Agilent Technologies is acquiring Stratagene for $10.94 per share, a 28% premium over the companies closing price on April 5, 2007. 

    “We see Stratagene’s technology, products and expertise as being highly complementary to Agilent’s life sciences portfolio, enabling us to offer our customers more complete workflow solutions,” comments Nick Roelofs, vp and general manager of Agilent’s Life Sciences Solutions Unit. “Stratagene has a strong R&D team as well as excellent presence in the important academic and government markets.”

    Stratagene will operate as a division within Agilent’s Life Sciences Solutions Unit. Both companies expect to see a broadened customer base.

    The companies expect that the merger will close in approximately 90 days. Approximately 59% of Stratagene stockholders have already agreed to vote in favor of the merger.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »